CorAssist Cardiovascular - Innovative Solutions for heart failure with preserved ejection fraction (HFpEF)
Over 5.7 million people in the US
and 20 million people worldwide
suffer from heart failure.
CorAssist Cardiovascular - Innovative Solutions for Heart Failure with Preserved Ejection Fraction (HFpEF)

News

  • July 2017

    First implantation at RAMBAM Medical Center. Video available here: https://www.youtube.com/watch?v=Iy0iL1cKG2s

  • 2017

    CORolla® TAA First-in-man stand-alone clinical study initiated in Rambam Health Care Campus and is now recruiting patients.

  • EuroPcr 2015

    May 19–22, 2015. Paris, France

  • November 2013

    San Francisco, California - CorAssist presents at the TCT 2013 Conference the 6 months follow-up results of first patient implanted with the CORolla® device, which indicate device safety, together with improvement in diastolic function parameters.

  • March 2013

    CorAssist Cardiovascular announces first patient treated with the CORolla® TAA implant add on to surgical valve replacement.

  • January 2013

    Two years results of the CORolla® pre-clinical study demonstrating safety before entering the clinical stage

  • February 2012

    CorAssist raises $4.8 Million from its current shareholders

  • January 2012

    One year results of the CORolla pre clinical study demonstrating safety

  • December 2011

    CorAssists is awarded the “Best Technology Parade Presentation” in the ICI 2011 Conference.

  • December 2010

    CorAssists is awarded the “Best Technology Parade Presentation” in the ICI 2010 Conference.

  • October 2010

    CorAssist presents 24 Months Safety in Humans and demonstrated trends of efficacy Implantation Demonstration Brings CORolla™ One Step Closer to the Clinic Events and presentations